Patents by Inventor Quirin Hammer

Quirin Hammer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTIVATION AND EXPANSION OF NKG2C+ NK CELLS
    Publication number: 20210023163
    Abstract: The invention relates to an isolated peptide for use as a medicament, wherein said peptide has 9 to 30 amino acids and comprises or consists of an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), preferably V, L, I or F. The invention further relates to the peptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells. The invention further relates to the peptide of the invention for use in the treatment and/or prevention of a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2. Additionally, the invention relates to a genetically modified virus encoding a peptide comprising or consisting of a polypeptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Inventors: Chiara Romagnani, Timo Rückert, Quirin Hammer
  • Activation and expansion of NKG2C+ NK cells
    Patent number: 10864245
    Abstract: The invention relates to an isolated peptide for use as a medicament, wherein said peptide has 9 to 30 amino acids and comprises or consists of an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), preferably V, L, I or F. The invention further relates to the peptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells. The invention further relates to the peptide of the invention for use in the treatment and/or prevention of a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2. Additionally, the invention relates to a genetically modified virus encoding a peptide comprising or consisting of a polypeptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 15, 2020
    Assignee: DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN
    Inventors: Chiara Romagnani, Timo Rückert, Quirin Hammer
  • ACTIVATION AND EXPANSION OF NKG2C+ NK CELLS
    Publication number: 20190314445
    Abstract: The invention relates to an isolated peptide for use as a medicament, wherein said peptide has 9 to 30 amino acids and comprises or consists of an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), preferably V, L, I or F. The invention further relates to the peptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells. The invention further relates to the peptide of the invention for use in the treatment and/or prevention of a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2. Additionally, the invention relates to a genetically modified virus encoding a peptide comprising or consisting of a polypeptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells.
    Type: Application
    Filed: March 15, 2019
    Publication date: October 17, 2019
    Inventors: Chiara Romagnani, Timo Rückert, Quirin Hammer